๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› EU
Clinical trial register · European Union · CTIS

Recently authorised EU trials

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show โ€” this register states both numbers rather than picking one.

Download CSV
Source: EMA Clinical Trials Information System (CTIS). Showing the 2500 most recently authorised of 12467 total CTIS records โ€” a stated recency window, not the full historical archive. Synced 22 Sep 2026, 03:17 UTC
2500
Shown in this register
most recently authorised
12,467
Total on CTIS
full historical archive
744
Phase III
within the shown window
Top member states
Spain 1018 France 887 Germany 856 Italy 735 Poland 580 Netherlands 527
Narrow the register
Phase
Phase I 557 Phase I/II 211 Phase II 727 Phase III 744 Phase IV 261
Lead sponsor
AstraZeneca AB 62 Assistance Publique Hopitaux De Paris 49 Merck Sharp & Dohme LLC 47 Pfizer Inc. 44 Novo Nordisk A/S 43
Member state
Spain 1018 France 887 Germany 856 Italy 735 Poland 580 Netherlands 527 Belgium 424 Czechia 329
All 28 states
2500 of 2500 shown studies
Download
Phase
Study
Lead sponsor
Area
Member states
Decision
Phase III
ZENITH: A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
2025-522960-34-00Hypertension, Established cardiovascular disease, High cardโ€ฆ
Alnylam Pharmaceuticals Inc.
Cardiovascular Diseases
Belgium, Hungary, Czechia, Austria, Germany, France, Greece, Spain, Romania, Netherlands, Italy, Poland, Slovakia, Sweden, Portugal, Denmark, Bulgaria
03/02/2026
Phase III
A Phase 3b/4 Randomized, Open-label, Efficacy Assessor-Blinded Study, to Evaluate the Efficacy and Safety of Upadacitinib for the Treatment of Adult Subjects with Moderate to Severe Atopic Dermatitis and Inadequate Response to Dupilumab (SWITCH-UP)
2025-523347-35-00Atopic Dermatitis
AbbVie Deutschland GmbH & Co. KG
Immune System Diseases
Spain, Italy, Romania
02/02/2026
Phase III
A Pilot Study on the Use of Gadopiclenol for Enhanced Cardiac MRI in Children with Congenital Heart Conditions: A self-controlled, non-randomised, open-label study to compare the image quality and diagnostic performance of gadopiclenol versus gadoterate meglumine
2025-524029-41-00Cardiomyopathy, tetralogy of Fallot, or complex congenital โ€ฆ
Fundacio Sant Joan De Deu
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Spain
02/02/2026
Phase III
MAMI Use of the Methoxyflurane as pain-killer in the prehospital management of Acute Myocardial Infarction
2025-523349-86-00Acute Myocardial Infarction
Assistance Publique Hopitaux De Paris
Cardiovascular Diseases
France
02/02/2026
Phase III
NACRE 2_Randomized phase III study evaluating two treatment strategies for locally advanced rectal cancer in patients โ‰ฅ75 years old
2025-521619-37-00Patients โ‰ฅ75 years old with cT3/T4 rectal adenocarcinoma elโ€ฆ
Unicancer
Neoplasms
France
02/02/2026
Phase I
A clinical study of MK-1045 in people with lupus or rheumatoid arthritis (MK-1045-004)
2025-523412-36-00Systemic lupus erythematosus, Rheumatoid arthritis
Merck Sharp & Dohme LLC
Immune System Diseases
Italy, Belgium, Romania
02/02/2026
Phase I
A Study of JNJ-90301900 in Combination with Concurrent Chemoradiation Therapy in LA HNSCC
2025-522914-22-00Locally Advanced Head and Neck Squamous Cell Carcinoma (LA โ€ฆ
Janssen Cilag International
Neoplasms
France, Spain
02/02/2026
Phase II
A Phase 2b, Randomised, Double-Blind, Placebo-Controlled, Parallel-Arm Dose Finding Study Evaluating the Efficacy and Safety of SAB-142 for Delaying the Progression of Type 1 Diabetes (T1D) in Patients with Stage 3 New Onset of Type 1 Diabetes (NOT1D)
2025-521560-36-00Type 1 Diabetes
Sab Biotherapeutics Inc.
Nutritional and Metabolic Diseases
Austria, Germany, Poland, Italy, Denmark, Spain, Belgium, Finland, France, Lithuania, Slovenia
02/02/2026
Phase I
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Maribavir Tablets 200 mg, manufactured by Sun Pharmaceutical Industries Limited, India with LIVTENCITYยฎ (Maribavir) Coated Tablets 200 mg, manufactured by: Catalent CTS, LLC Kansas City, United States of America, packed by: Takeda Ireland Limited Bray, Ireland, imported by: Takeda Pharma Ltda. Highway SP 340 S/N, km 133.5 Jaguariรบna Administrative Building -SP CNPJ 60.397.775/0001-74 SAC: 0800 - 7710345, in healthy adult, human subjects under fasting condition.
2025-523487-21-00cytomegalovirus (CMV) infection and/or disease that is refrโ€ฆ
Sun Pharmaceutical Industries Limited
Virus Diseases
Romania
02/02/2026
Phase II
ASPIRE-1: Individual and combined endothelin receptor and SGLT2 antagonism in adults with type 1 diabetes mellitus and chronic kidney disease: a Phase 2, multicenter, open-label randomized cross-over trial
2023-504404-28-00Chronic Kidney Disease, Type 1 Diabetes
University Medical Center Groningen
Nutritional and Metabolic Diseases
Netherlands, Finland, Denmark
02/02/2026
Phase I
Safety and tolerability of medicated chewing gum with sodium alginate, calcium carbonate and sodium bicarbonate.
2025-524102-15-00No medical condition.
Laboratorios Liconsa S.A.
Not possible to specify
Portugal
02/02/2026
Phase II
Efficacy and safety of SP16 in preventing Acute Kidney Injury in at-risk subjects with chronic kidney disease undergoing elective cardiac surgery using the heart-lung-machine: A prospective, randomized, double-blind, placebo-controlled clinical trial (EASE-AKI)
2025-522491-89-00Cardiovascular Disease, Valvular Disease, Chronic Kidney Diโ€ฆ
Universitaetsklinikum Erlangen AรถR
Cardiovascular Diseases
Germany
02/02/2026
Phase III
A Phase III, Multicentre, Open-Label, Randomised Study Evaluating the Efficacy and Safety of R-mini-CHOP x2 followed by AZD0486 versus R-mini-CHOP x6 in Elderly or Unfit Participants with Newly Diagnosed Large B-cell Lymphoma (SOUNDTRACK-D2)
2025-522029-37-00Large B-cell Lymphoma
AstraZeneca AB
Neoplasms
Poland, Belgium
30/01/2026
Phase I/II
An open label, phase I/II study investigating the safety and efficacy of a CD3/CD20 bispecific T-cell engager therapy in patients with active, treatment refractory, ANCA-IgG-positive associated vasculitis. The RENEWAL study
2025-522853-21-01Active, treatment refractory, ANCA-IgG-positive associated โ€ฆ
Fraunhofer Institute For Translational Medicine And Pharmacology ITMP
Immune System Diseases
Germany
30/01/2026
Phase III
A Phase 2b/3, Adaptive, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Danicamtiv in Participants with Symptomatic Genetic and Familial Dilated Cardiomyopathy (KINSHIP-DCM).
2025-522553-19-00Symptomatic genetic and familial dilated cardiomyopathy.
Kardigan Inc.
Cardiovascular Diseases
Spain, Denmark, Belgium, Hungary, Italy, Poland, France, Sweden, Netherlands
30/01/2026
Phase I
A study to find how safe different doses of LFD-200 are and how it works in both healthy people and people with moderate to severe rheumatoid arthritis
2025-523409-13-00Moderate to Severe Rheumatoid Arthritis
Lifordi Immunotherapeutics Inc.
Immune System Diseases
Poland
30/01/2026
Phase I
PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND IMMUNOGENICITY OF E-VIM VACCINE CVX1 WITH OR WITHOUT ICI IN THE TREATMENT OF SUBJECTS WITH MUSCLE INVASIVE BLADDER CANCER (MIBC) OR LOCALIZED OR LOCALLY ADVANCED RENAL CELL CANCER (RCC).
2025-523781-25-00metastatic solid cancer, muscle invasive bladder cancer, loโ€ฆ
CimCure B.V.
Neoplasms
Netherlands
29/01/2026
Phase I/II
First-in-human, Open-label, Multi-site, Phase I/IIa, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of BNT329 in Participants With Advanced Solid Tumors Known to Express CA19-9
2025-522613-26-00Advanced Solid Cancers
BioNTech SE
Neoplasms
Spain, Germany
29/01/2026
Phase I/II
A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-DM1 in Subjects With Type 1 Myotonic Dystrophy Who are โ‰ฅ18 to โ‰ค65 Years
2024-513579-42-00Type 1 Myotonic Dystrophy
Sarepta Therapeutics Inc.
Nervous System Diseases
Spain, Germany, Belgium, Italy
29/01/2026
Phase III
J2S-MC-GZMP: A Phase 3, Multicenter, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Brenipatide Compared With Placebo for the Treatment of Adult Participants With Alcohol Use Disorder (RENEW-ALC-2)
2025-522312-16-00Alcohol Use Disorder
Eli Lilly & Co.
Behavioral Disciplines and Activities
Germany, Belgium
29/01/2026
Phase III
A RANDOMIZED, PHASE 3, OPEN-LABEL STUDY OF NEOADJUVANT DAROVASERTIB IN SUBJECTS WITH PRIMARY NON-METASTATIC UVEAL MELANOMA (OptimUM-10)
2025-522387-32-00Uveal Melanoma
Ideaya Biosciences Inc.
Eye Diseases
France, Spain, Poland, Italy, Czechia, Belgium, Austria, Netherlands, Denmark, Germany
29/01/2026
Phase IV
Changes in Coronary Plaque Composition By Semaglutide Use in Diabetic Patients With Acute Coronary Syndrome: A Randomized Optical Coherence Tomography Trial - ARMYDA - 10 study
2025-523977-40-00non-ST-elevation myocardial infarction (NSTEMI); unstable aโ€ฆ
Azienda Ospedaliero-Universitaria Maggiore Della Carita
Cardiovascular Diseases
Italy
28/01/2026
Phase IV
Tailored antiplatelet secondary prevention in non-cardioembolic ischemic stroke: a phase IV gender-stratified randomized controlled trial (TAILOR trial)
2025-523065-16-00Non-cardioembolic ischemic stroke
Azienda Unita Sanitaria Locale Di Bologna
Cardiovascular Diseases
Italy
28/01/2026
Phase II
Phase 2, Multicenter, Open label, Platform Study investigating ASP3082 in patients with Metastatic/Locally Advanced Non-Small-Cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), with biomarker analysis to characterize response/resistance (UNLOCK ASP3082)
2025-522533-54-00Metastatic Non-small cell lung cancer (NSCLC) and Pancreatiโ€ฆ
Institut Gustave Roussy
Neoplasms
France
28/01/2026
Phase III
Multicenter, randomized, double-blinded, placebo-controlled phase 3 trial to evaluate nonavalent HPV vaccine as a secondary prevention in patients treated for human papilloma virus related high-grade squamous intraepithelial lesions.(BioHPV)
2024-520140-42-00Patients with primary HPV high-grade squamous intra-epithelโ€ฆ
Institut Gustave Roussy
Neoplasms
France
28/01/2026
Phase I/II
Guttmann NeuroRecovery โ€“ Feasibility, safety and efficacy of intrathecal Wharton's jelly-derived mesenchymal stem cells and transcutaneous spinal cord stimulation in the rehabilitation of chronic spinal cord injuries: a pilot study
2025-521877-14-00Traumatic spinal cord injury
Fundacio Institut Guttmann
Nervous System Diseases
Spain
28/01/2026
Phase IV
Multicentre, open-label, randomized controlled non-inferiority trial comparing single dose intrathecal morphine and continuous thoracic epidural analgesia for multimodal analgesia in open colorectal surgery: the ColoREDIT protocol
2024-520262-58-01All diseases requiring resective colorectal surgery with a โ€ฆ
Region Vaestmanland
Anesthesia and Analgesia
Sweden
28/01/2026
Phase II
A Multi-Center, Double-Blind, Placebo-Controlled, Phase II Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489, A Monoacylglycerol Lipase Inhibitor, as Add-On Therapy to Ocrelizumab, in Participants with Progressive Forms of Multiple Sclerosis
2025-521636-10-00Progressive Forms of Multiple Sclerosis (PMS)
F. Hoffmann-La Roche AG
Nervous System Diseases
Germany, Spain, France, Hungary, Italy, Poland, Portugal
28/01/2026
Phase IV
EFFICACY OF INFILTRATED MEPIVACAINE AS A LOCAL ANESTHETIC PRIOR TO ARTERIAL PUNCTURE: A RANDOMIZED CONTROLLED CLINICAL TRIAL
2025-522974-35-00Respiratory disease. Prescripcion o indicaciรณn de gasometrรญโ€ฆ
University Of The Basque Country
Respiratory Tract Diseases
Spain
28/01/2026
Phase I
A study in healthy people or otherwise healthy with overweight or obesity to compare 2 formulations of survodutide given in different ways, either as a pre-filled syringe or a pen-like injector
2024-519614-30-00Healthy volunteer trial
Boehringer Ingelheim International GmbH
Not possible to specify
Germany
28/01/2026
Phase II
Antisense Oligonucleotide Eye Drops against IRS-1 to Optimize Pretransplant Lymphangio-regression Prior to High-Risk Keratoplasty (Olisens-Precon)
2025-522099-10-00Pathologically prevascularized corneas due to herpetic keraโ€ฆ
University Of Cologne
Eye Diseases
Germany
28/01/2026
Phase IV
The efficacy of pipamperone and aripiprazole on behaviors that challenge in people with intellectual disabilities: A series of N-of-1 cross-over trials
2024-519833-51-00Behaviors that challenge
Stichting GGZ Drenthe
Behavioral Disciplines and Activities
Netherlands
28/01/2026
Phase I
Study to look at the safety, tolerability, and how the body processes the study medicine WAL0623 after single or repeated doses, with or without food, in healthy volunteers
2024-516446-18-00Glomerular kidney diseases with proteinuria
Walden Biosciences Inc.
Male Urogenital Diseases
Italy
27/01/2026
Phase III
An Open-label, Multicenter, Randomized, Non-Inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Weekly Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Patients with Alpha1-Antitrypsin Deficiency Compared to Corresponding Standard 60 mg/kg/week and 120 mg/kg/week Doses of Intravenous Alpha1-Proteinase Inhibitor (5%)
2025-522792-29-00Alpha-1 Antitrypsin Deficiency
Grifols Therapeutics LLC
Respiratory Tract Diseases
Poland, Denmark, Netherlands, Ireland, Sweden, Spain, Portugal, Germany, France
27/01/2026
Phase III
N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD
2025-522674-36-00Metabolic Dysfunction-Associated Steatotic Liver Disease
Eli Lilly & Co.
Nutritional and Metabolic Diseases
Czechia, France, Netherlands, Bulgaria, Norway, Austria, Poland, Spain, Italy, Hungary, Germany, Romania, Sweden, Portugal, Belgium
27/01/2026
Phase I/II
A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of Etentamig Monotherapy or Etentamig Combinations in Subjects with Multiple Myeloma
2024-515770-27-00Multiple Myeloma
AbbVie Deutschland GmbH & Co. KG
Neoplasms
Norway
27/01/2026
Phase III
Test-Retest Evaluation of [18F]F-AraG in Lung Tumors (TREAT)
2025-522404-24-01Lung Cancer
Amsterdam UMC Stichting
Neoplasms
Netherlands
27/01/2026
Phase I
A PK study to compare JPB898 (proposed nivolumab biosimilar) and US-licensed Opdivoยฎ in participants with resected stage IIB, IIC, or III melanoma in the adjuvant setting
2025-521919-39-00Resected stage IIB, IIC, or III melanoma requiring adjuvantโ€ฆ
H e x a l AG
Neoplasms
Spain, Romania, Italy, Greece
27/01/2026
Phase IV
Exploring the Psychoactive Effects of Paracetamol: A parallel group, basic science, double blind, two armed study, to investigate potential emotional and cognitive effects of paracetamol (tablet form) compared to a placebo (tablet form) in healthy male and female participants between ages 18 and 30.
2025-522753-19-02Healthy adults aged 18-30.
Oslo Metropolitan University
Psychological Phenomena
Norway
27/01/2026
Phase IV
Intrathecal baclofen pump versus selective dorsal rhizotomy for non-ambulatory children with cerebral palsy
2024-518822-33-01Cerebral Palsy
UZ Leuven
Nervous System Diseases
Netherlands, Belgium
27/01/2026
Phase IV
Early Lyophilised plasma In Patients with haemorrhagic Shock (ELIPS-Trial)
2025-523151-66-00Haemorrhagic shock
Johannes Kepler University Linz
Anesthesia and Analgesia
Austria
26/01/2026
Phase III
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallelgroup Study to Evaluate the Efficacy and Safety of Treprostinil Palmitil Inhalation Powder in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease
2025-521558-40-00Pulmonary Hypertension Associated with Interstitial Lung Diโ€ฆ
Insmed Inc.
Respiratory Tract Diseases
Portugal, Italy, Czechia, Poland, Denmark, Greece, Germany, Romania, Spain, France, Belgium, Austria
26/01/2026
Phase I/II
Evaluation of a [68Ga] Ga-HER2 single domain antibody PET/CT for predicting pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) in HER2-positive early breast cancer
2025-523286-23-00Breast Cancer
Centre Henri Becquerel
Not possible to specify
France
26/01/2026
Phase III
Patient-Centered Study of Trastuzumab Deruxtecan (T-DXd) in First-Line HER2-POsitive Metastatic Breast Cancer with Proactive Toxicity ManagementReflecting Real-World Clinical Practice / TOP-REAL Trial
2025-521805-41-00Patients with HER2-positive, locally advanced or metastaticโ€ฆ
Solti Group
Neoplasms
France, Germany, Spain
26/01/2026
Phase I
Safety, Tolerability and Efficacy against Controlled Human Malaria Infection of PfSPZ-LARC2 Vaccine in Malaria-naรฏve Adults
2024-518273-34-02Malaria
Universitaetsklinikum Tuebingen AรถR
Parasitic Diseases
Germany
26/01/2026
Phase II
PASSION (olaParib mAintenance in chemotherapy-Sensitive metaStatic pancreatIc adenOcarciNoma - mPDAC): a phase II, proof of principle, study
2025-522530-31-01Patients with metastatic PDAC, who have not progressed follโ€ฆ
Universita' Degli Studi Di Verona
Neoplasms
Italy
26/01/2026
Phase III
An Operationally Seamless Phase 2/3 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Enlicitide Decanoate in Pediatric Participants with Heterozygous Familial Hypercholesterolemia
2024-519068-42-00โ€‹Heterozygous Familial Hypercholesterolemiaโ€‹ in pediatric pโ€ฆ
Merck Sharp & Dohme LLC
Cardiovascular Diseases
Germany, Spain, Belgium, Czechia, Norway, France, Poland, Netherlands, Italy, Finland
26/01/2026
Phase IV
Morphine PCA vs Morphine and Lidocaine PCA for the treatment of vaso-occlusive crisis-related pain in sickle-cell anaemia patients: a prospective, randomized, double blind monocentric trial.
2025-523777-41-01sickle cell anaemia
CHU Saint Pierre
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Belgium
26/01/2026
Phase I
A study understanding how much CDR132L enters the bloodstream after injection under the skin compared to injection into a vein in healthy participants
2025-521329-34-00Healthy volunteers, treatment for heart failure
Novo Nordisk A/S
Cardiovascular Diseases
Germany
26/01/2026
Phase I
A study to investigate the effect of capivasertib on the pharmacokinetics of oral dextromethorphan (CYP2D6) in healthy participants
2025-523995-21-00Healthy participants
AstraZeneca AB
Not possible to specify
Germany
26/01/2026
Phase III
A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate Azetukalner in Moderate-to-Severe Major Depressive Disorder
2025-523202-32-00Major Depressive Disorder
Xenon Pharmaceuticals Inc.
Mental Disorders
Spain, Czechia, Slovakia, Romania, Poland, Finland, Germany
26/01/2026
Phase IV
A multicenter, prospective clinical TRrial evaluating patientโ€™s ability to make an independent and safe decision regarding the USe of the medicinal product Sildenafil Polpharma100 mg indicated in the Treatment of erectile dysfunction. TRUST Trial on Responsible Use and Self-assessed Treatment.
2025-522923-81-00Erectile dysfunction
ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.
Male Urogenital Diseases
Poland
26/01/2026
Phase I
A Phase 1, Randomized, Double-Blind, Two-Arm, Two-Way Crossover Study of Pharmacokinetics and Pharmacodynamics of QL0911
2025-523355-59-00Immune Thrombocytopenia, Hematopoietic Syndrome of Acute Raโ€ฆ
Qilu Pharmaceutical Co. Ltd.
Hemic and Lymphatic Diseases
Poland
26/01/2026
Phase III
J2A-MC-GZPS: A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared with Placebo in Female Participants with Stress Urinary Incontinence Who Have Obesity or Overweight (RESTRAIN-SUI) ; J2A-MC-GZS1: A Study to Investigate Efficacy and Safety of Orforglipron Once Daily in Participants with Stress Urinary Incontinence Who Have Obesity or Overweight ; J2A-MC-GZS2: A Study to Investigate Efficacy and Safety of Orforglipron Once Daily in Participants with Stress Urinary Incontinence Who Have Obesity or Overweight
2025-522514-23-00Urinary Incontinence, Stress
Eli Lilly & Co.
Female Urogenital Diseases and Pregnancy Complications
Romania, Czechia, Poland
26/01/2026
Phase II
SARUPANC - A multicentric, single arm, phase II trial assessing the efficacy of suraparib as first line therapy for patients with metastatic homologous repair-deficient pancreatic cancer
2024-516558-24-00Pancreatic (PAAD)
Centre Leon Berard
Neoplasms
France
23/01/2026
Phase III
CIRAANO: Multimodal exploration (including radiopharmaceuticals Amyvidยฎ and Tauvidยฎ) of theater actors, memory athletes, and patients with various memory pathologies: evaluation of mnesic strategies and their cerebral substrates, and contribution to the treatment of memory pathologies.
2025-523264-21-00Semantic Variant Primary Progressive Aphasia, Alcohol Use Dโ€ฆ
Institut National De La Sante Et De La Recherche Medicale
Mental Disorders
France
23/01/2026
Phase II
Evaluation of Tildrakizumab in the Treatment of Ocular Sequelae in Lyell syndrome
2025-522556-10-01Ocular Sequelae in Lyell syndrome
TOXILYON
Eye Diseases
France
23/01/2026
Phase II
Antisense Oligonucleotide Eye Drops Against IRS-1 to Treat Pathological Corneal Neovascularisation in Aniridia-Associated Keratopathy (Olisens-Aniridia)
2025-522609-39-00Corneal Neovascularization in Aniridia-associated Keratopatโ€ฆ
University Of Cologne
Eye Diseases
Germany
23/01/2026
Phase II
A Phase II, Randomized, Open-Label Study Evaluating Two Inavolisib Dose Levels in Combination with Fulvestrant in Participants with PIK3CA-Mutated, HR-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
2025-522805-39-00Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic suโ€ฆ
F. Hoffmann-La Roche AG
Neoplasms
Belgium, Spain
23/01/2026
Phase II
An open-label, single-arm extension study to evaluate the long-term safety, tolerability, and efficacy of leniolisib for immune dysregulation in patients with primary immunodeficiency
2025-522444-40-00primary immunodeficiency
Pharming Technologies B.V.
Immune System Diseases
Spain
23/01/2026
Phase II
Master Protocol: A Phase 1b / 2, Multicenter, Multi Arm Study of Evorpacept in Combination with Anti-cancer Therapies in Advanced / Metastatic Malignancies (ASPEN-09) Substudy Protocol: A Single-arm Phase 2 Multicenter Study of Evorpacept in Combination with Trastuzumab and Chemotherapy in Participants with Metastatic HER2-Positive Breast Cancer (ASPEN-09-03)
2025-522012-16-00Breast Cancer
Alx Oncology Holdings Inc.
Neoplasms
Spain, Italy, France
23/01/2026
Phase III
Phase 3 Study to Evaluate the Efficacy and Safety of Zodasiran in Adolescent and Adult Subjects with Homozygous Familial Hypercholesterolemia (YOSEMITE)
2025-521792-31-01Homozygous Familial Hypercholesterolemia (HoFH)
Arrowhead Pharmaceuticals Inc.
Cardiovascular Diseases
Greece, France, Belgium, Germany, Netherlands, Austria, Sweden, Spain, Czechia, Italy
23/01/2026
Phase I
A Study Evaluating the Safety and Tolerability of a Novel Formulation of QRL-101 in Healthy Participants
2025-524310-28-00Epilepsy, amotrophic lateral sclerosis, neuropathy
Quralis Corp.
Nervous System Diseases
Netherlands
23/01/2026
Phase II
A Phase 2b Randomized, Open-Label Active Controlled Study Evaluating the Safety and Efficacy of oral VH4524184 Coadministered with Emtricitabine and Tenofovir Alafenamide in Treatment Naรฏve Viremic Persons with HIV-1.( INNOVATE Study)
2025-521918-26-00HIV Infections
Viiv Healthcare UK Limited
Virus Diseases
Spain, Belgium, France, Germany, Italy, Portugal, Poland
23/01/2026
Phase I
An open label safety and efficacy study of allogenic adipose tissue-derived mesenchymal stromal cells on autism and gastrointestinal symptoms
2025-523699-21-00Gastrointestinal symptoms, Autism spectrum disorder
Cell to Cure ApS
Mental Disorders
Denmark
23/01/2026
Phase III
Study on the influence of FLUMAzenil regarding the incidence of pediatric emergence delirium (ED) in children undergoing ENT surgery โ€“ FLUMA Study
2025-523543-36-00pediatric emergence delirium
Rheinische Friedrich-Wilhelms-Universitaet Bonn
Not possible to specify
Germany
23/01/2026
Phase I/II
A First-in-Human, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of Intrathecally Administered LTX-002 in Adult Participants with Amyotrophic Lateral Sclerosis
2025-522039-33-00Amyotrophic Lateral Sclerosis
Leal Therapeutics Inc.
Nervous System Diseases
Sweden, Italy, Germany, Netherlands
23/01/2026
Phase II
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Dose Comparison and Exploratory Efficacy Study of Orally Administered SAT-3247 in Ambulatory DMD Patients
2025-522522-13-01Duchenne muscular dystrophy
Satellos Bioscience Inc.
Nervous System Diseases
Spain, Belgium, Poland
22/01/2026
Phase III
Evaluation of a New Pain Management Regime for Oocyte Pick-Up During Fertility Treatment
2025-523018-10-00Acute procedural pain associated with oocyte pick-up (oocytโ€ฆ
UZ Brussel
Anesthesia and Analgesia
Belgium
22/01/2026
Phase I
(22597) A study to learn about how safe nitroglycerin is and how it affects the body when taken along with nurandociguat in people with coronary artery disease.
2025-522335-34-00Chronic kidney disease, Coronary artery disease
Bayer AG
Cardiovascular Diseases
Germany, Bulgaria
22/01/2026
Phase I
An Experimental Medicine multicenter Trial to evaluate the safety and immunogenicity of experimental versus authorized SARS-CoV-2 vaccine candidates as a booster dose in healthy participants previously vaccinated with authorized mRNA SARS-CoV-2 vaccines.
2025-520652-28-00healthy participants
ANRS Maladies Infectieuses Emergentes
Pathological Conditions, Signs and Symptoms
France
21/01/2026
Phase II
The effect of CBD on sleep quality following late evening exercise
2024-518609-17-00healthy individuals
UZ Leuven
Physiological processes
Belgium
21/01/2026
Phase IV
The effect op corticosteroids on quality of life following total hip arthroplasty: HIPSTER study
2025-524368-39-00Patients aged 60 years or older undergoing total hip arthroโ€ฆ
Ziekenhuis Oost Limburg
Anesthesia and Analgesia
Belgium
21/01/2026
Phase II
Psilocybin AsSisted pSychotherapy for the treatmENt of Gambling disordER : a pilot study
2025-522743-18-00Gambling disorder
Centre Hospitalier Universitaire De Nantes
Behavior and Behavior Mechanisms
France
21/01/2026
Phase II
J2S-MC-GZMR: A Phase 2, Multicenter, Randomized, Double-blind, 52-week Study, to Investigate the Efficacy and Safety of Brenipatide Compared with Placebo for the Treatment of Adult Participants with Uncontrolled Moderate to Severe Asthma
2025-522640-41-00Asthma
Eli Lilly & Co.
Respiratory Tract Diseases
Germany, Netherlands, France, Poland
21/01/2026
Phase I/II
A PHASE 1/1B STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND IMMUNOGENICITY OF SINGLE AND MULTIPLE ASCENDING DOSES OF BCX17725 IN HEALTHY PARTICIPANTS AND MULTIPLE DOSES OF BCX17725 IN PARTICIPANTS WITH NETHERTON SYNDROME
2025-521973-16-00Netherton Syndrome
Biocryst Pharmaceuticals Inc.
Skin and Connective Tissue Diseases
France, Netherlands, Germany
20/01/2026
Phase II
A randomized, double-blind, placebo-controlled study to assess the effects of high concentration capsaicin patch (Qutenza) on neuropathic symptoms, nerve fibers, and microcirculation in painful diabetic peripheral neuropathy
2025-523597-17-00Painful diabetic peripheral neuropathy
Deutsche Diabetes Forschungsgesellschaft e.V.
Nervous System Diseases
Germany
20/01/2026
Phase II
A phase II, open label, multicenter trial investigating Irinotecan plus cetuximab rechallenge compared with trifluridine/tipiracil plus bevacizumab as third line treatment in circulating tumor DNA molecularly selected metastatic colorectal cancer: the ROMANCE-GOIM trial
2025-521319-38-00metastatic colorectal cancer
Gruppo Oncologico Dell'Italia Meridionale
Neoplasms
Italy
19/01/2026
Phase III
Beamion LUNG-3: A randomized, controlled, multi-center trial evaluating zongertinib as an adjuvant monotherapy compared with standard of care in patients with early-stage, resectable non-small cell lung cancer (Stage II-IIIB) harboring tyrosine kinase domain activating HER2 mutations
2025-521284-12-00Non-small cell lung cancer
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Neoplasms
Austria, Portugal, Netherlands, Greece, Belgium, Spain, Germany, France, Romania, Sweden, Italy, Denmark
19/01/2026
Phase III
IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-based Chemotherapy in Patients with EGFR-mutated Non-small Cell Lung Cancer and Disease Progression on EGFR Tyrosine Kinase Inhibitor Therapy
2025-521908-22-00EGFR-mutated Non-small Cell Lung Cancer
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Poland, Germany, Italy, Norway, Netherlands, Belgium, Romania, France, Greece, Spain
19/01/2026
Phase I/II
AdaptNK โ€“Cell Therapy for High-risk Myeloid Disease
2025-521962-83-00Relapsed and/or refractory AML or MDS
Karolinska Institutet
Hemic and Lymphatic Diseases
Sweden
19/01/2026
Phase II
A Phase 2, Open-Label, Randomized, Master Protocol Dose Optimization Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations with Mirvetuximab Soravtansine in Subjects with Ovarian Cancer (FLORENZA)
2025-521606-18-00Ovarian Cancer
AbbVie Deutschland GmbH & Co. KG
Neoplasms
Spain, Czechia, France, Belgium, Denmark
19/01/2026
Phase III
A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PRAGMATYK)
2023-503766-24-00Moderate to Severe Plaque Psoriasis
Bristol-Myers Squibb Services Unlimited Company
Immune System Diseases
Romania, Bulgaria, Germany, Spain, Czechia, France, Hungary, Italy, Sweden, Poland, Denmark, Belgium
19/01/2026
Phase IV
International multicentre, open-label, phase IV clinical trial to evaluate the efficacy, safety and effect on quality of life of bilastine in children with allergic rhinoconjunctivitis
2024-519550-36-00Allergic rhinoconjunctivitis
Faes Farma S.A., A. Menarini Industrie Farmaceutiche Riunite S.r.l.
Immune System Diseases
Poland, Spain, Italy
19/01/2026
Phase III
Fluorescence Intraoperative Surgical Margin Analysis in Head and Neck Cancer: Clinical Validation
2025-522027-95-00oral squamous cell carcinoma
Universitair Medisch Centrum Groningen
Neoplasms
Netherlands
19/01/2026
Phase IV
The impact of extra-fine inhalation corticosteroid particles on small-airway disease in Chronic Obstructive Pulmonary Disease (COPD): a randomized, prospective cross-over trial.
2025-524256-64-00Chronic Obstructive Pulmonary Disease
CHU Saint Pierre
Respiratory Tract Diseases
Belgium
19/01/2026
Phase I
A study to determine the safety and effect of antibodies against hepatitis D (the SAMBA-D study)
2025-522125-36-00Chronic hepatitis D infection
Region Midtjylland
Virus Diseases
Germany, Denmark
19/01/2026
Phase I/II
DREPAMIR - A Phase 1/2 Open Label Cohort Comparative Study Evaluating the Efficacy and the safety of Gene Therapy of the Sickle Cell Disease by Transplantation of an Autologous CD34+ enriched cell fraction that contains autologous CD34+ cells transduced ex vivo by the bifunctional ฮฒAS3m/miR7m lentiviral vector expressing the ฮฒAS3m and a micro-RNA (miRNA) targeting specifically the endogenous ฮฒS-globin mRNA in Patients with Sickle Cell Disease (SCD)
2025-521257-17-00SCD severe patients
Assistance Publique Hopitaux De Paris
Hemic and Lymphatic Diseases
France
16/01/2026
Phase I/II
A Phase 1/2 dose escalation trial with administration schedule exploration evaluating single agent TD001, a PSMA-targeted antibody-drug conjugate, in patients with PSMA-expressing metastatic castration-resistant prostate cancer
2025-523273-41-00Metastatic castration-resistant prostate cancer
T.O.A.D. Oncology S.A.
Neoplasms
Spain, France
16/01/2026
Phase II
A Phase 2a, Randomized, Double-Blind, Parallel-Group, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fexlamose (AER 01) Inhalation Solution in the Treatment of Adults with Moderate to Severe Chronic Obstructive Pulmonary Disease
2025-523020-50-00Chronic Obstructive Pulmonary Disease
Aer Therapeutics Inc.
Respiratory Tract Diseases
Bulgaria, Poland, Spain
16/01/2026
Phase III
Melatonin versus placebo for bipolar disorder - a double blinded randomised controlled trial (The M-bipolar RCT)
2025-523549-92-00Bipolar disorder
Region Hovedstaden
Mental Disorders
Denmark
16/01/2026
Phase I
First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS)
2025-523101-15-00Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risโ€ฆ
Genmab A/S
Neoplasms
Denmark, Spain
16/01/2026
Phase I
A Phase 1 Study for ZW251 in Participants with Solid Tumors.
2025-523088-39-00Advanced Solid Tumors
Zymeworks Bc Inc.
Neoplasms
Portugal, Ireland, Spain
15/01/2026
Phase I
A trial to learn how safe AZD5335 is and if a drug called itraconazole changes how AZD5335 moves through the body over time in adults with ovarian, peritoneal, or fallopian tube cancer
2025-522731-34-00Ovarian cancer Primary peritoneal cancer Fallopian tube canโ€ฆ
AstraZeneca AB
Neoplasms
Spain, Ireland, Portugal
15/01/2026
Phase I
A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants with Advanced Solid Tumors Previously Treated with Standard of Care Therapy
2025-521614-26-00Advanced Solid Tumors
AstraZeneca AB
Neoplasms
Spain
15/01/2026
Phase III
An open-label, parallel, Phase 3, two-arm study to investigate the efficacy and safety of fitusiran prophylaxis in male participants aged 1 to less than 12 years with hemophilia A or B with or without inhibitory antibodies to Factors VIII or IX
2025-521858-42-00Hemophilia
Sanofi-Aventis Recherche & Developpement
Hemic and Lymphatic Diseases
Belgium, Italy, Romania, Germany, Hungary, Spain, Poland
15/01/2026
Phase II
A Randomized, Placebo-controlled, Parallel Phase 2a Dose-ranging Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated with Epidermal Growth Factor Receptor Inhibitors CLEER Trial (Chemotherapy Longevity by Evading EGFR Inhibitor Reactions)
2025-523058-16-00Skin Toxicities Associated with Epidermal Growth Factor Recโ€ฆ
Hoth Therapeutics Inc.
Skin and Connective Tissue Diseases
Spain, Hungary, Poland
15/01/2026
Phase III
A Phase 3, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Individuals with Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
2025-521845-26-00BP-I mania or mania with mixed features
Bristol-Myers Squibb Services Unlimited Company
Mental Disorders
Romania, Poland, France, Italy, Denmark, Bulgaria
15/01/2026
Phase III
HOVON 181 AML: Bleximenib or Placebo in Combination with Standard Induction and Consolidation Therapy followed by Maintenance for the Treatment of Patients with Newly Diagnosed KMT2A-rearranged or NPM1-mutant Acute Myeloid Leukemia Eligible for Intensive Chemotherapy: a double-blind phase 3 study
2025-522767-15-00Acute Myeloid Leukemia
Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
Neoplasms
Belgium, Netherlands, Germany, Austria, Denmark, Estonia, Finland, Ireland, Italy, Lithuania, Spain, Sweden, Norway, Poland
15/01/2026
Phase II
A phase 2, three-arm, randomized study of the efficacy of intratumorally administered L19IL2 or L19TNF or L19IL2/L19TNF, all in combination with systemic anti-PD1 pembrolizumab, in stage III and IV unresectable melanoma patients with resistance to or progressing upon anti-PD1 checkpoint inhibitors and with presence of injectable metastases
2024-519326-20-00Patients with diagnosis of unresectable clinical stage III โ€ฆ
Philogen S.p.A.
Neoplasms
Italy, Germany
14/01/2026
Rows per page Showing 1601–1700 of 2500
Previous 15 16 17 18 19 Next
Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS). Derived from the EMA Clinical Trials Information System. Retrieved 22 September 2026. https://priyalifescience.com/clinical-trials-europe?page=17

Query this register directly
GET /api/export.php?register=trials-eu&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.